Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

REUBEN MARI VALENZUELA

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1922328103
CMS profile
87116
Location
PEORIA, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$125,131.62

273 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 4 of 6; records 151–200 of 273 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

REUBEN MARI VALENZUELA

NPI 1922328103 · CMS profile ID 87116

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

PEORIA, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 6; records 151–200 of 273 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1922328103?year=2025&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
REUBEN MARI VALENZUELA, NPI 1922328103, CMS profile ID 87116. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 273 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922328103?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). REUBEN MARI VALENZUELA, NPI 1922328103, CMS profile ID 87116. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 273 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922328103?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
REUBEN MARI VALENZUELA, NPI 1922328103, CMS profile ID 87116, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 6; records 151–200 of 273 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1922328103?year=2025&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

273 matching records · $125,131.62 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 273 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 273.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
EMD Serono, Inc. $41.9406/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236886836 CMS
Celgene Corporation $18.1106/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184544203 CMS
Janssen Biotech, Inc. $22.6006/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174327841 CMS
Medtronic, Inc. $23.1406/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219112744 CMS
Biogen, Inc. $112.6706/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208414913 CMS
Novartis Pharmaceuticals Corporation $20.6306/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200394426 CMS
Eisai Inc. $31.7106/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244507521 CMS
Vanda Pharmaceuticals Inc. $102.2006/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233010165 CMS
Vanda Pharmaceuticals Inc. $4,313.0006/11/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233010167 CMS
Vanda Pharmaceuticals Inc. $114.8006/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233010169 CMS
Amgen Inc. $19.0406/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228678231 CMS
TG Therapeutics, Inc. $1,013.0006/10/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1226203977 CMS
ABBVIE INC. $7.3306/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204611828 CMS
ANI Pharmaceuticals, Inc. $26.5206/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248653679 CMS
TG Therapeutics, Inc. $143.4606/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226203903 CMS
Amneal Pharmaceuticals LLC $29.5206/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1220551892 CMS
Merz Pharmaceuticals, LLC $37.8906/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232566508 CMS
TG Therapeutics, Inc. $30.3606/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226203965 CMS
ABBVIE INC. $15.9605/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204611824 CMS
Neurocrine BioSciences, Inc. $17.4205/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243035644 CMS
ABBVIE INC. $11.8905/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204611820 CMS
ABBVIE INC. $5.8505/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204611816 CMS
Eisai Inc. $14.0205/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244507523 CMS
EMD Serono, Inc. $103.6805/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236921267 CMS
Janssen Biotech, Inc. $28.4705/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174327834 CMS
ARGENX US, INC. $84.6705/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240439276 CMS
TG Therapeutics, Inc. $13.1805/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226203915 CMS
TG Therapeutics, Inc. $20.4305/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226203953 CMS
Teva Pharmaceuticals USA, Inc. $23.0905/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247245348 CMS
Amneal Pharmaceuticals LLC $13.8605/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1220551890 CMS
PFIZER INC. $16.6105/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230040735 CMS
TG Therapeutics, Inc. $10.1005/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226203911 CMS
UCB, Inc. $112.0005/13/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224486412 CMS
UCB, Inc. $2,500.0005/13/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224486414 CMS
Novartis Pharmaceuticals Corporation $9.6405/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200394422 CMS
Neurelis, Inc. $18.9105/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219202982 CMS
Neurocrine BioSciences, Inc. $10.5305/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243049189 CMS
Vanda Pharmaceuticals Inc. $9.0105/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233010163 CMS
Biogen, Inc. $16.8405/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208486719 CMS
EMD Serono, Inc. $7,735.0005/05/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1236867218 CMS
Mallinckrodt Hospital Products Inc. $28.1805/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212005305 CMS
TG Therapeutics, Inc. $2.9305/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226203945 CMS
TG Therapeutics, Inc. $20.1505/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226203973 CMS
UCB, Inc. $25.0004/30/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224486406 CMS
UCB, Inc. $125.0004/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224486408 CMS
UCB, Inc. $158.4604/30/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224486410 CMS
ANI Pharmaceuticals, Inc. $20.9804/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248647391 CMS
Eisai Inc. $17.9704/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244507519 CMS
ABBVIE INC. $27.7404/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204611812 CMS
Amgen Inc. $14.8704/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227241070 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $41,973.56 123
PY2020 $44,503.62 94
PY2021 $94,679.80 156
PY2022 $129,181.43 181
PY2023 $76,162.77 210
PY2024 $78,312.94 234
PY2025 $125,131.62 273

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $21,191.75 14
PY2024 Principal investigator $114,645.27 40
PY2023 Principal investigator $65,723.60 44
PY2022 Principal investigator $68,916.60 62
PY2021 Principal investigator $22,628.75 36
PY2020 Principal investigator $55,553.84 53
PY2019 Principal investigator $22,813.14 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

14 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 EMD Serono, Inc. $345.00 09/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118191
Principal investigator 1 EMD Serono, Inc. $1,200.00 09/09/2025 Non-covered Recipient Entity
PRAIRIE EDUCATION AND RESEARCH COOPERATIVE
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118465
Principal investigator 1 GENZYME CORPORATION $15,262.75 09/08/2025 Non-covered Recipient Entity
Springfield Clinic Llp
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226081556
Principal investigator 1 GENZYME CORPORATION $65.00 08/25/2025 Non-covered Recipient Entity
Springfield Clinic Llp
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226081559
Principal investigator 1 GENZYME CORPORATION $260.00 08/25/2025 Non-covered Recipient Entity
Springfield Clinic Llp
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226081564
Principal investigator 1 GENZYME CORPORATION $180.00 08/25/2025 Non-covered Recipient Entity
Springfield Clinic Llp
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226081568
Principal investigator 1 GENZYME CORPORATION $65.00 08/25/2025 Non-covered Recipient Entity
Springfield Clinic Llp
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226081572
Principal investigator 1 GENZYME CORPORATION $180.00 08/25/2025 Non-covered Recipient Entity
Springfield Clinic Llp
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226081576
Principal investigator 1 GENZYME CORPORATION $65.00 08/25/2025 Non-covered Recipient Entity
Springfield Clinic Llp
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226081582
Principal investigator 1 GENZYME CORPORATION $65.00 08/25/2025 Non-covered Recipient Entity
Springfield Clinic Llp
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226081586
Principal investigator 1 EMD Serono, Inc. $1,345.00 05/22/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118195
Principal investigator 1 GENZYME CORPORATION $375.00 04/02/2025 Non-covered Recipient Entity
Springfield Clinic Llp
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226081478
Principal investigator 1 EMD Serono, Inc. $1,280.00 03/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118199
Principal investigator 1 EMD Serono, Inc. $504.00 03/18/2025 Non-covered Recipient Entity
PRAIRIE EDUCATION AND RESEARCH COOPERATIVE
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118463